BioNxt Secures European Patent for Sublingual Cladribine Technology

BioNxt Solutions Inc. has announced a significant milestone with the European Patent Office's decision to grant a patent for its sublingual cladribine drug delivery technology. The patent, effective upon its official publication on March 11, 2026, will protect the technology across 39 European countries until at least June 2043.

This development is part of BioNxt's strategic move to strengthen its presence in Europe, a major pharmaceutical market. CEO Hugh Rogers highlights the importance of this patent in enhancing global intellectual property rights and supporting licensing discussions. The company's technology aims to improve the delivery of cladribine for multiple sclerosis treatment, offering a needle-free option that dissolves in the mouth.

The patent also encompasses the use of cladribine for other autoimmune and neurodegenerative diseases. BioNxt has taken steps to expand its patent coverage globally, including in the U.S., Canada, and Eurasian regions, as it gears up for clinical studies to validate the bioavailability of its formulation.